Publicacións en colaboración con investigadores/as de Hospital Universitario de Getafe (10)

2024

  1. Real-world safety and effectiveness of dapagliflozin in people living with type 1 diabetes in Spain: The Dapa-ON multicenter retrospective study

    Diabetes and Metabolism, Vol. 50, Núm. 1

2023

  1. Clinical Significance of T2-Weighted Sequence Intensity on Magnetic Resonance Imaging in Clinically Non-Functioning Pituitary Adenomas

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, Vol. 131, Núm. 12, pp. 631-638

  2. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

    Frontiers in Endocrinology, Vol. 14

2022

  1. Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma

    Journal of Neuro-Oncology, Vol. 160, Núm. 2, pp. 351-359

2020

  1. Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

    Endocrine, Vol. 70, Núm. 3, pp. 575-583

2015

  1. Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: Association with clinical presentation and response to treatments

    European Journal of Endocrinology, Vol. 172, Núm. 2, pp. 115-122

2013

  1. Insuficiencia suprarrenal y su tratamiento sustitutivo. Su realidad en España

    Endocrinologia y Nutricion

  2. Pegvisomant and cabergoline combination therapy in acromegaly

    Pituitary, Vol. 16, Núm. 1, pp. 101-108

  3. Weight-related quality of life in spanish obese subjects suitable for bariatric surgery is lower than in their north american counterparts: A case-control study

    Obesity Surgery, Vol. 23, Núm. 4, pp. 509-514

2006

  1. Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: A phase III trial

    Clinical Endocrinology, Vol. 65, Núm. 3, pp. 320-326